Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 121 results for psychosis

  1. Is clozapine clinically and cost effective when compared with other pharmacological interventions for people with psychosis and coexisting substance misuse?

    when compared with other pharmacological interventions for people with psychosis and coexisting substance misuse? Any explanatory...

  2. What are the risks that predict the development of blood-borne virus infections in people with complex psychosis in the UK?

    the development of blood-borne virus infections in people with complex psychosis in the UK? Any explanatory notes(if applicable) Care and

  3. Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124

  4. What tailored interventions (pharmaceutical and psychological) specific to rehabilitation are effective at equipping people with complex psychosis with the ability to live in the community?

    specific to rehabilitation are effective at equipping people with complex psychosis with the ability to live in the community? Any...

  5. What structured group activities are effective at improving interpersonal functioning (social skills) for people with complex psychosis?

    improving interpersonal functioning (social skills) for people with complex psychosis? Any explanatory notes(if applicable)...

  6. Is providing treatment for psychosis and substance misuse services within staffed accommodation more cost-effective than a combination of hospital and home treatment?

    Recommendation ID CG120/3 Question Is providing treatment for psychosis and substance misuse services within staffed accommodation more...

  7. Is an integrated care system effective at promoting successful progress for people with complex psychosis to a more independent setting?

    system effective at promoting successful progress for people with complex psychosis to a more independent setting? Any explanatory...

  8. The physical health benefits of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks?

    of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks? Any...

  9. Peer support interventions:- What is the clinical and cost effectiveness of peer support interventions in people with psychosis and schizophrenia?

    clinical and cost effectiveness of peer support interventions in people with psychosis and schizophrenia? Any explanatory notes(if...

  10. Bipolar, schizophrenia and other psychoses: annual blood glucose or HbA1c (IND159)

    This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood glucose or HbA1c in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM130

  11. What is the efficacy and cost effectiveness of rehabilitation services compared with treatment as usual for people with complex psychosis with residual disability, who are leaving early intervention services?

    rehabilitation services compared with treatment as usual for people with complex psychosis with residual disability, who are leaving...

  12. Cardiovascular disease prevention: cardiovascular risk assessment for people with bipolar, schizophrenia or other psychoses (IND150)

    This indicator covers the percentage of patients aged between 25 and 84 years with schizophrenia, bipolar affective disorder and other psychoses (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a full formal cardiovascular disease risk assessment performed in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM120

  13. What are the prevalence, risk and protective factors, and course of illness for different combinations of psychosis and coexisting substance misuse (for example, schizophrenia and cannabis misuse or bipolar disorder and alcohol misuse)?

    protective factors, and course of illness for different combinations of psychosis and coexisting substance misuse (for example,...

  14. Medication choice in people with coexisting conditions:- What is the clinical and cost effectiveness of ADHD medications in people with ADHD and tic disorders, a history of psychosis or mania, or personality disorder?

    of ADHD medications in people with ADHD and tic disorders, a history of psychosis or mania, or personality disorder? Any explanatory...

  15. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.